Jay M.  Short net worth and biography

Jay Short Biography and Net Worth

CEO of BioAtla
Dr. Short is a cofounder of BioAtla© and co-inventor of the BioAtla's patented Conditionally Active Biologics (CAB) platform. He also cofounded Diversa Corporation (now BASF), a pioneering developer of enzymes, antibodies and biologically active compounds, and served in multiple roles including CEO, President and CTO from 1994 to 2005. He led Diversa's public offering, raising over $200 million, which was the largest biotechnology IPO at that time. Prior to Diversa, Dr. Short served as President of Stratacyte, an antibody engineering company and subsidiary of Stratagene (now Agilent), which together with Scripps Clinic was the first to clone and screen human antibody libraries in E. coli. During this time he also served as VP of R&D and Operations for Stratagene Cloning Systems. Dr. Short received his B.A in Chemistry with Honors from Taylor University. At Case Western Reserve University he received his Ph.D. in Biochemistry with additional studies in Macromolecular Science. He is the author of more than 100 publications and is the inventor of over 500 issued patents.

In 2006, Dr. Short was shortlisted by the editors of Nature Biotechnology as one of the people who made the most significant contribution to biotech in the past decade. He is the recipient of numerous other awards, including Ernst & Young's Entrepreneur of the Year Award, the American Chemical Society's Henry F. Whalen, Jr. Award for Business Development, Adaptive Business Leaders' Innovations in HealthCare Gold Award, two of Connect's first place Most Innovative Product Awards, and in 2010 received an international Best-of-the-Best award from the Young Presidents Organization (YPO). Dr. Short's board experience includes 15 years as a director of Invitrogen (now Thermo Fisher), Senomyx, and Taxon Biosciences (now Dupont). He is a member of YPO/WPO and a founder of Capia IP and the E.O. Wilson Biodiversity Foundation. Dr. Short serves as an advisor to educational, commercial, scientific and charitable organizations.

What is Jay M. Short's net worth?

The estimated net worth of Jay M. Short is at least $537,284.34 as of December 20th, 2023. Dr. Short owns 1,439,283 shares of BioAtla stock worth more than $537,284 as of March 29th. This net worth estimate does not reflect any other assets that Dr. Short may own. Additionally, Dr. Short receives an annual salary of $1,130,000.00 as CEO at BioAtla. Learn More about Jay M. Short's net worth.

How old is Jay M. Short?

Dr. Short is currently 66 years old. There are 3 older executives and no younger executives at BioAtla. Learn More on Jay M. Short's age.

What is Jay M. Short's salary?

As the CEO of BioAtla, Inc., Dr. Short earns $1,130,000.00 per year. Learn More on Jay M. Short's salary.

How do I contact Jay M. Short?

The corporate mailing address for Dr. Short and other BioAtla executives is , , . BioAtla can also be reached via phone at 858-558-0708 and via email at investors@bioatla.com. Learn More on Jay M. Short's contact information.

Has Jay M. Short been buying or selling shares of BioAtla?

Jay M. Short has not been actively trading shares of BioAtla during the last ninety days. Most recently, on Wednesday, December 20th, Jay M. Phd Short bought 50,000 shares of BioAtla stock. The stock was acquired at an average cost of $2.14 per share, with a total value of $107,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,439,283 shares of the company's stock, valued at $3,080,065.62. Learn More on Jay M. Short's trading history.

Who are BioAtla's active insiders?

BioAtla's insider roster includes Guy Levy (Director), Jay Short (CEO), Eric Sievers (Insider), Scott Smith (President), Lawrence Steinman (Director), Christian Vasquez (Insider), and Richard Waldron (CFO). Learn More on BioAtla's active insiders.

Jay M. Short Insider Trading History at BioAtla

See Full Table

Jay M. Short Buying and Selling Activity at BioAtla

This chart shows Jay M Phd Short's buying and selling at BioAtla by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

BioAtla Company Overview

BioAtla logo
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.37
Low: $0.28
High: $0.38

50 Day Range

MA: $0.40
Low: $0.30
High: $0.51

2 Week Range

Now: $0.37
Low: $0.24
High: $4.02

Volume

1,443,415 shs

Average Volume

994,354 shs

Market Capitalization

$18.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19